Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5441_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Contents
- •Editors and Contributors
- •1.1 Introduction
- •1.2 Preformulation Studies
- •1.2.1 Solubility
- •1.2.2 Partition Coefficient
- •1.3.2 Parenteral Dosage Forms
- •1.3.3 Oral Dosage Form
- •1.3.4 Transdermal Dosage Form
- •1.3.5 Inhalational Formulation
- •1.3.6 Nasal Formulations
- •1.3.7 Ophthalmic Dosage Form
- •1.4 Scale-Up Studies
- •1.4.1 Pilot Plant
- •1.4.2 Current Good Manufacturing Practices (cGMP)
- •1.2.4 Bulk Properties
- •1.3 Prototype Development
- •1.4.3 Regulatory Approval
- •1.5 Commercialisation
- •1.5.1.5 Life Cycle Extension Strategies
- •1.8 Conclusion
- •References
- •2.1 Introduction
- •2.1.2 Product Specification
- •2.1.3.1 In-Process Specification
- •2.1.3.2 Release Specification
- •2.1.3.3 Shelf Life Specification
- •2.1.4 Specification Design
- •2.1.5 Specification Justification
- •2.2.3 ICH Q6A Guideline
- •2.2.3.1 Objective
- •2.2.3.2 New Drug Product
- •2.2.3.3 New Drug Substance
- •2.2.3.4 Universal Tests
- •2.2.3.5 Specific Tests
- •2.2.4 ICH Q6B Guideline
- •2.2.4.1 Scope
- •2.2.4.2 Specifications
- •2.2.5.1 Q8(R2): Structure—Parent Guideline (Knight 2014)
- •2.2.5.1.1 Pharmaceutical Development: Introduction
- •Drug Substances
- •Excipients
- •2.2.5.1.3 Drug Product
- •Formulation Development
- •Overages
- •2.2.5.1.4 Manufacturing Process Development
- •2.2.5.1.5 Container Closure System
- •2.2.5.1.6 Microbiological Attributes
- •2.2.5.1.7 Compatibility
- •2.2.5.2 Q8(R2): Structure—Annex
- •2.2.5.2.1 Introduction
- •Quality Target Product Profile
- •Critical Quality Attributes (CQA)
- •Design Space
- •Control Strategy
- •Design Space
- •Control Strategy
- •Drug Substance-Related Information
- •2.3 Conclusion
- •References
- •3.1 Introduction
- •3.3.1 Factorial Designs (FD)
- •3.3.2 Fractional Factorial Designs (FFDs)
- •3.3.3 Plackett–Burman Designs (PBDs)
- •3.3.4 Central Composite Designs (CCD)
- •3.3.5 Box–Behnken Designs (BBD)
- •3.3.6 Equiradial Designs
- •3.3.7 Mixture Designs
- •3.3.8 Taguchi Designs
- •3.3.9 Optimal Designs
- •3.4.1 Quality Target Product Profile (QTPP)
- •3.4.2 Critical Quality Attributes (CQAs)
- •3.4.3 Risk Management
- •3.4.4 Design Space
- •3.4.5 Control Strategy
- •3.6.2 Constraint-Based Optimization
- •3.6.3 Multi-objective Optimization
- •3.6.4 Expert Systems
- •3.6.5 Evolutionary Algorithms
- •3.9.1 Design-Expert
- •3.9.2 SIMCA
- •3.9.3 Minitab
- •3.9.4 JMP
- •3.9.5 MATLAB
- •3.9.6 Aspen Plus
- •3.9.7 AutoCAD
- •3.10.1 Pharmaceutical Industry
- •3.10.2 Food Industry
- •3.10.3 Chemical Industry
- •3.10.4 Biotechnology Industry
- •3.11 Conclusion
- •References
- •4.3.1.1 Fillers/Diluents
- •4.3.1.2 Binders
- •4.3.2.2 Solubilisers
- •4.3.2.3 Sweeteners
- •4.3.2.4 pH Adjusters
- •4.3.2.5 Preservatives
- •4.3.2.6 Surfactant
- •4.3.2.7 Suspending Agent
- •4.3.2.8 Emulsifying Agent
- •4.3.2.9 Colorants
- •4.3.2.10 Viscosity Modifiers
- •4.3.3.1 Penetration Enhancers
- •4.3.3.2 Solvents/Solubilisers
- •4.3.3.3 Adhesives
- •4.3.3.5 Plasticisers
- •4.3.4.1.1 Bulking Agents
- •4.3.4.1.2 Lyoprotectants
- •4.3.4.1.3 Antioxidants
- •4.3.4.1.4 Buffering Agents
- •4.3.4.2.1 Buffers
- •4.3.4.2.2 Preservatives
- •4.3.4.2.3 Tonicity Adjusters
- •4.3.4.2.4 Solvent System
- •4.3.4.2.5 Solubilisers
- •4.4.1 Physical Incompatibilities
- •4.4.2 Chemical Incompatibilities
- •4.3.1.3 Disintegrants
- •4.3.1.5 Coating Agents
- •4.3.1.8 Solubilisers
- •4.3.2.1 Vehicles
- •4.4.3 Therapeutic or Physiological Incompatibilities
- •4.6 Related Regulatory Perspectives
- •4.6.1 GRAS
- •4.6.2 IIG
- •4.6.3 IPEC
- •4.7 Conclusion
- •References
- •5.1 Introduction
- •5.2.1 Binders
- •5.2.1.1 Hydroxy Propyl Methyl Cellulose (HPMC)
- •5.2.1.2 LYCATAB
- •5.2.1.3 GalenIQ (Isomalt)
- •5.2.2 Disintegrants
- •5.2.3 Lubricants
- •5.2.4 Co-processed Excipients
- •5.2.4.2 COMBILOSE
- •5.2.4.3 PEARLITOL CR-H
- •5.2.4.4 PROSOLV EASYtab SP (Silicified Microcrystalline Cellulose)
- •5.3 New-Age Material Handling Techniques Developed
- •5.3.1 Automated Dispensing System
- •5.3.1.1 Unit Dose Dispensing Systems
- •5.3.1.2 Centralised Dispensing Systems
- •5.3.1.3 Robotic Dispensing Systems
- •5.3.2 Vacuum Conveying Systems
- •5.3.3 Flexible Screw Conveyors
- •5.4.1 Automation
- •5.4.2 Enhanced Safety
- •5.4.3 Higher Productivity
- •5.4.4 Enhanced Accuracy
- •5.4.5 Reduced Costs
- •5.6.1 Widely Used Databases
- •5.6.5.1 Tablets
- •5.6.5.2 Predicting Drug Release
- •5.6.5.4 Detecting Tablet Defects
- •5.6.5.5 Granules
- •5.7 Continuous Manufacturing Technology
- •5.7.1.1 Regulatory Uncertainties
- •5.7.1.2 Process Automation Technologies (PAT)
- •5.7.1.3 Equipment
- •5.7.1.5 Modern Process Control Techniques
- •5.8.1 Selective Laser Sintering (SLS)
- •5.8.1.1 Process Variables
- •5.8.2 Applications
- •5.8.2.1 Stereolithography (SLA)
- •5.8.2.2 Printing Dosage Forms
- •5.8.3.1 Fused Deposition Modelling (FDM)
- •5.8.3.3 Drawbacks
- •5.8.4.1 On-Demand Manufacturing
- •5.8.4.2 Improved Quality Dosage Forms
- •5.9 Summary
- •References
- •6.1 Introduction
- •6.2 Excipients
- •6.2.1 Superdisintegrants
- •6.2.3 Lubricants/Anti-adherents
- •6.2.4 Solubility/Dissolution Enhancers
- •6.2.5 Drug Release Rate Modifiers
- •6.2.6 Co-processed Excipients
- •6.3.1 Advanced Granulation Approaches
- •6.4 Process Automation
- •6.4.2 Fundamental Process Control Instruments
- •6.4.2.2 Rotary Tablet Press
- •6.5.1 Capping
- •6.5.2 Lamination
- •6.5.3 Chipping
- •6.5.4.1 Double Impression
- •6.6 Tablet Coating
- •6.6.1 Sugar Coating
- •6.6.2 Film Coating
- •6.7.1 Electrostatic Coating
- •6.7.2 Aqueous Film Coating Technology
- •6.7.3 Supercell Coating Technology (SCT)
- •6.7.4 Magnetically Assisted Impaction Coating (MAIC)
- •6.7.5 Dip Coating
- •6.7.6 Vacuum Film Coating
- •6.9 Conclusion
- •References
- •7.1 Tablet Dosage Form
- •7.3 Global Market Analysis
- •7.4.1 Organ-Targeted Tablets
- •7.4.2 Modified Release Tablets
- •7.4.3 Miscellaneous
- •7.4.3.1 Chewable Tablets
- •7.4.3.2 Effervescent Tablets
- •7.4.3.3 Orodispersible Tablets
- •References
- •8.1 Introduction
- •8.2 Theoretical Considerations
- •8.2.1 Interfacial Properties
- •8.2.1.1 Surface Free Energy
- •8.2.1.2 Surface Potential
- •8.2.2 Electric Double Layer (EDL)
- •8.2.4 Wetting
- •8.2.5 Electrokinetic Phenomena
- •8.2.6 DLVO Theory
- •8.3.1 Flocculated Suspension
- •8.3.2 Deflocculated Suspension
- •8.4 Pharmaceutical Suspension Stability Study
- •8.4.1 Particle Settling
- •8.4.2 Particle Aggregation
- •8.4.3 Particle Growth (Ostwald Ripening)
- •8.5.3 Redispersibility
- •8.5.4 Flow Rate (F)
- •8.5.5 Viscosity Determination
- •8.5.8 Temperature Effect
- •8.5.9 Drug Content
- •8.5.10 In Vitro Dissolution Studies
- •8.5.11 Zeta Potential
- •8.5.14 Density
- •8.6 Conclusion
- •References
- •9.1 Introduction
- •9.2.1 Macroemulsion
- •9.2.2 Microemulsion
- •9.2.3 Nanoemulsion
- •9.2.4 Pickering Emulsion
- •9.3.2 Surface Tension Theory
- •9.3.3 Molecular Adsorption Theory
- •9.3.4 Oriented Wedge Theory
- •9.4 Formulation
- •9.4.1.1 Dry Gum Method
- •9.4.1.2 Wet Gum Method
- •9.4.1.3 Bottle Method
- •9.4.1.4 In Situ Soap Method
- •9.4.1.5 Phase Titration Method
- •9.4.1.6 Phase Inversion Temperature Method
- •9.4.1.7 Spontaneous Emulsification
- •9.5 Stability
- •9.5.1 Gravitational Separation
- •9.5.1.1 Creaming
- •9.5.1.2 Sedimentation
- •9.5.1.3 Flocculation
- •9.5.2 Non-gravitational Separation
- •9.5.2.1 Coalescence
- •9.5.2.2 Droplet Aggregation
- •9.5.2.3 Ostwald Ripening
- •9.5.2.4 Phase Inversion
- •9.6 Evaluation
- •9.6.1 Macroscopic Evaluation
- •9.6.2 Microscopic Evaluation
- •9.6.3 Droplet Size Analysis
- •9.7 Conclusion
- •References
- •10.1 Introduction
- •10.2.1 Antimicrobial Preservatives
- •10.2.2 Antioxidants
- •10.2.3 Buffers
- •10.2.4 Vitamins
- •10.2.4.1 Vitamin B Complex
- •10.2.4.2 Vitamin C
- •10.2.4.3 Vitamin D
- •10.2.5 Electrolytes
- •10.2.6 Sodium
- •10.2.7 Potassium
- •10.2.8 Calcium
- •10.2.9 Magnesium
- •10.2.10 Chloride
- •10.2.12 Manganese
- •10.2.13 Selenium
- •10.2.14 Amino Acids
- •10.2.15 Carbohydrates
- •10.2.16 Dextrose
- •10.2.17 Lipids
- •10.3.1 Nutritional Support
- •10.3.2 Role of Parentral Admixture in Nutritional Deficiencies
- •10.3.3 Therapeutic Benefits
- •10.4.1.2 Aseptic Techniques
- •10.4.1.3 Dosing Considerations
- •10.5.1.1 FDA Guidelines
- •10.5.1.2 EMA Standards
- •10.6 Conclusion
- •References
- •11.1 Introduction
- •11.2.1 Drug Solubility
- •11.2.2 Drug Stability
- •11.2.3 Skin Irritation
- •11.3 Manufacturing Challenges
- •References
- •12.1 Introduction
- •12.2.1.3 Corneal Tissue Compatibility
- •12.2.1.4 Isotonicity
- •12.2.1.6 Viscosity (Appropriate Rheological Properties)
- •12.3.1 In Situ Gelling System
- •12.3.2 Mucoadhesives
- •12.3.4 Ophthalmic Nano-Suspensions
- •12.3.6 Therapeutic Contact Lenses
- •12.3.7 Ocular Inserts
- •12.4.1 Corneal Tissue Bioprinting
- •12.4.2 Contact Lens
- •12.4.3 Drug Delivery
- •12.6.1 Physical Appearance
- •12.6.2 Identification
- •12.6.3 Assay
- •12.6.4 Impurities
- •12.6.6 Antimicrobial Preservatives
- •12.6.7 Bacterial Endotoxins
- •12.6.9 Sterility Test
- •12.6.10 Osmolarity
- •12.6.11 Ocular Irritation
- •12.6.12 Isotonicity Evaluation
- •12.6.13 Stability Study
- •12.6.14 pH
- •12.6.15 Viscosity
- •12.8 Conclusion
- •References
- •13.1 Introduction
- •13.2.1 Improved Dissolution Rate by Surface Area Enlargement
- •13.3.1 Top-Down Approaches
- •13.3.1.1 Wet Bead Milling
- •13.3.1.2 Evaporation/Condensation
- •13.3.1.3 High-Pressure Homogenization
- •13.3.1.4 Laser Ablation
- •13.3.1.5 Ultrasound
- •13.3.2 Bottom-Up Approaches
- •13.3.2.1 Precipitation
- •13.3.2.2 Sol-Gel
- •13.3.2.4 Liquid Antisolvent Precipitation
- •13.3.2.5 Precipitation Assisted by Acid-Base Method
- •13.3.2.6 High Gravity-Controlled Precipitation
- •13.3.2.7 Supercritical Fluid (SCF) Method
- •13.3.2.8 Emulsion Polymerization Method
- •13.3.3 Combinative Technology
- •13.3.3.1 Nano Edge Technology
- •13.3.3.2 Smart Crystal Technology
- •13.4.2 SEM
- •13.4.3 TEM
- •13.4.4 AFM
- •13.4.6 Zeta Potential
- •13.4.7 DSC
- •13.4.8 XRD
- •13.4.9 FTIR
- •13.4.10 Raman Spectroscopy
- •13.4.11 TGA
- •13.4.12 Permeation Study
- •13.5.1 Oral Delivery
- •13.5.2 Parenteral Administration
- •13.5.3 Pulmonary Drug Delivery
- •13.5.4 Ocular Drug Delivery
- •13.5.5 Topical Drug Delivery
- •13.5.6 Targeted Drug Delivery
- •13.7 Conclusion
- •References
- •14.1 Introduction
- •14.2.1 Device-Related Challenges
- •14.2.2 Biological Barriers
- •14.3.1 Nebulizers
- •14.3.1.1 Conventional Nebulizers
- •14.3.1.1.1 Jet Nebulizers
- •14.3.1.1.2 Ultrasonic Nebulizer
- •14.3.1.2.1 Mesh Nebulizer
- •14.3.1.2.2 Vibrating Mesh Nebulizer (VMN)
- •14.3.2 Dry Powder Inhalers
- •14.3.2.2.1 Active Devices
- •14.3.2.2.2 Digital/Smart Devices
- •14.3.3 Metered Dose Inhaler (MDI)
- •14.3.3.1.2 Extra-Fine Particle Atomization
- •References
- •15.1 Introduction
- •15.2.1 Herbal Nanoemulsion
- •15.2.2 Herbal Nanoparticles
- •15.2.3 Herbal Hydrogels
- •15.4.1 Thermal Analysis
- •15.4.2 High-Performance Thin-Layer Chromatography (HPTLC)
- •15.4.3 High-Performance Liquid Chromatography (HPLC)
- •15.4.4 Liquid Chromatography Mass Spectrometry (LCMS)
- •15.4.5 Supercritical Fluid Chromatography
- •15.4.6 Gas Chromatography-Mass Spectrometry (GCMS)
- •15.4.7 Inductively Coupled Plasma-Mass Spectroscopy
- •15.5.1 Physical Instability
- •15.5.2 Environmental Conditions
- •15.5.3 Chemical Instability
- •15.5.4 Complex Mixtures
- •15.7 Conclusion
- •References
- •16.1 Introduction
- •16.3 Approaches
- •16.3.1 Phenotypic Screening
- •16.3.2 Target-Based Methods
- •16.3.3 Knowledge-Based Methods
- •16.3.4 Signature-Based Methods
- •16.3.5 Pathway or Network-Based Methods
- •16.3.6 Targeted Mechanism-Based Methods
- •16.3.7 Pharmacovigilance-Based Drug Repurposing
- •16.4 Virtual Screening (VS)
- •16.4.1 Molecular Docking
- •16.4.2 Ligand-Based Virtual Screening (LBVS)
- •16.4.3 Pharmacophore Modelling
- •16.4.4 Similarity Searching
- •16.4.5 Machine Learning (ML)
- •16.4.6 Structure Based
- •16.4.7 Molecular Dynamics Studies
- •16.4.8 Quantitative Structure-Activity Relationship (QSAR)
- •16.4.9.1.1 AutoDock
- •16.4.9.1.2 Chimera
- •16.4.9.1.3 Discovery Studio
- •16.4.9.1.4 Dock
- •16.4.9.1.5 MolDock
- •16.4.9.1.6 Argus Lab
- •16.5 Conclusion
- •References
- •17.1 Introduction
- •17.2 Pre-clinical Evaluations
- •17.2.1 In Vitro Pharmacological Studies
- •17.2.2 In Vivo Toxicity Studies
- •17.2.3 In Vivo Efficacy Studies
- •17.3 Clinical Evaluations
- •17.3.1 Clinical Trial Phases
- •17.3.1.1 Phase 0
- •17.3.1.2 Phase I
- •17.3.1.3 Phase II
- •17.3.1.4 Phase III
- •17.4 Pharmacovigilance
- •17.4.2 Clinical Trial Designs
- •17.4.3 Randomized Controlled Trials
- •17.4.3.1 Parallel Arm Design
- •17.4.3.2 Cross-Over Design
- •17.4.3.3 Randomized Withdrawal Design
- •17.4.3.4 Factorial Design
- •17.4.4.1 Stratified Randomization
- •17.4.4.2 Block Randomization
- •17.4.4.3 Cluster Randomization
- •17.5 Pharmacogenomics
- •17.5.1 Pharmacokinetic Gene Variation
- •17.5.2 Pharmacodynamics Gene Variation
- •17.7 Conclusions
- •References

250
evaluating its performance through various parameters such as accuracy, precision,
specicity, linearity, and robustness. Additionally, we assessed the stability of ampi-
cillin in TPN admixtures under different storage conditions. The results demon-
strated the method’s reliability and accuracy in quantifying ampicillin, ensuring the
safe and effective administration of this antibiotic in clinical settings (Stawny
etal. 2019).
The investigators evaluated the physical and chemical stability of ibuprofen
when mixed with various lipid emulsions and PN solutions, assessing factors like
particle size, pH, and concentration. Their ndings indicated that ibuprofen was
compatible with certain lipid emulsions and PN solutions, but incompatibilities
were observed with others, leading to precipitation or phase separation. These
results provide valuable guidance for healthcare professionals to ensure the safe and
effective administration of intravenous ibuprofen in combination with lipids and PN
solutions, avoiding potential complications and improving patient care (Garcia
etal. 2018).
Physical and chemical stability of ciprooxacin was evaluated in combination
with various parentral solutions, assessing factors like precipitation, crystallization,
and concentration. Findings revealed that ciprooxacin compatibility with PN
admixtures was dependent on factors like pH, temperature, and nutrient composi-
tion. Specically, they identied potential incompatibilities and instability when
ciprooxacin was mixed with certain PN solutions, which could lead to reduced
efcacy or adverse effects. These results provide essential guidance for healthcare
professionals to ensure the safe and effective co-administration of ciprooxacin and
PN admixtures, optimizing patient care and outcomes (Gostyńska etal. 2019).
They focused on ensuring the safe co-administration of loop diuretics with par-
enteral nutrition (PN) solutions and conducted invitro compatibility tests to inves-
tigate potential interactions between these medications and PN admixtures. They
evaluated the physical and chemical stability of loop diuretics (such as furosemide
and bumetanide) when mixed with various PN solutions, assessing factors like pre-
cipitation, crystallization, and concentration changes. The results revealed potential
incompatibilities and instability when certain loop diuretics were combined with
specic PN solutions, which could impact drug efcacy and patient safety. This
provides valuable insights for healthcare professionals, informing the development
of evidence-based guidelines for the safe co-administration of loop diuretics and PN
solutions in clinical practice (Tomczak etal. 2020).
This investigation highlighted a critical safety concern regarding the co-
administration of sodium valproate, an anticonvulsant medication, with parenteral
nutrition (PN) admixtures. Researchers conducted invitro tests to evaluate the com-
patibility of sodium valproate with PN solutions, revealing signicant incompatibil-
ities that could compromise patient safety. Specically, they found that sodium
valproate precipitated out of solution when mixed with certain PN admixtures, lead-
ing to reduced drug concentration and potential treatment failure. Moreover, the
precipitate formed could potentially cause infusion-related reactions or other
adverse effects. This study’s ndings underscore the importance of careful evalua-
tion of drug-PN compatibility to ensure safe and effective treatment and highlight
S. Shilpi et al.

251
the need for alternative administration strategies to avoid potential harm to patients
(Piwowarczyk etal. 2022; Tomczak etal. 2023).
The antiemetic medications, such as ondansetron and metoclopramide were
mixed with parentral solutions for pediatric use and further studied for its physio-
chemical stability. Their ndings revealed potential incompatibilities and instabil-
ity, including precipitation and crystallization, which could impact drug efcacy
and patient safety. The study identied specic compatibility issues and provided
recommendations for alternative administration strategies, such as separate infusion
lines or adjusted drug concentrations. These results contribute to the development of
evidence-based guidelines for the safe co-administration of antiemetic drugs and
PN solutions in pediatric care, minimizing potential risks and improving treatment
outcomes (Tomczak etal. 2023; Riera etal. 2018).
This study examined the physical and chemical stability, as well as sterility, of
standard parenteral nutrition (PN) solutions and simulated Y-site admixtures spe-
cically designed for neonatal care. The effects of mixing PN solutions with other
medications and nutrients on the stability and sterility of the admixtures showed that
certain combinations and concentrations led to precipitation, crystallization, and
microbial growth, compromising the safety and efcacy of the PN solutions. The
study identied optimal conditions and guidelines for preparing and administering
PN solutions and Y-site admixtures in neonatal care, ensuring the delivery of stable
and sterile nutrition to vulnerable newborns (Riera etal. 2018).
The compatibility of various calcium and phosphate concentrations in different
solution types, considering factors like pH, temperature, and nutrient composition,
established safe limits for calcium and phosphate content in neonatal parenteral
solutions, ensuring that these critical nutrients can be delivered effectively and
safely to newborns without compromising solution stability or patient well-being
and providing valuable guidance for healthcare professionals along with nutrition-
ists to optimize parenteral nutrition regimens for neonates (Watrobska-
Swietlikowska 2019).
10.2 Additives inLarge Volume Parenteral
10.2.1 Antimicrobial Preservatives
To prevent microbial growth in multiple-dose as well as single-dose parenteral
products, an appropriate antimicrobial agent is added (Table10.2). The selection of
antimicrobial agents is very important; it basically depends on the preservatives,
function, and effect of the active pharmaceutical ingredient of the parenteral prod-
uct. Phenol and benzyl alcohol are the two most common antimicrobial preserva-
tives used in peptide and protein products, while phenoxyethanol is the most
frequently used preservative in vaccines. Benzyl alcohol or a combination of meth-
ylparaben and propylparaben is generally found in small-molecule parenteral for-
mulations (Meyer etal. 2007; Pramanick etal. 2013).
10 Sterile Products andAdmixtures

252
10.2.2 Antioxidants
The antioxidants are added in parenteral product to prevent the oxidation of API and
other additives which enhance the shelf life of parenteral product. Antioxidants are
classied into four classes such reducing agent, blocking agent, synergistic agent,
and chelating agent (Table10.3).
The most commonly used antioxidants in the sterile formulations are ascorbic
acid, acetylcysteine, sulfurous acid salts (bisulte, metabisulte), monothioglyc-
erol, acetone sodium bisulte (0.2–0.4% w/v), argon (100%), ascorbyl palmitate,
and sodium ascorbate.
10.2.3 Buffers
The solubility and stability of the substance of many drugs depend on the pH of the
solution. The pH of parenteral preparation may be changed during storage due to
leaching the content of rubber or plastic closure in the prepration, entrapment of
gases and vapors, chemical reaction with glass container, and reaction within for-
mulation. Buffers are added to a formulation to adjust and stabilize pH and optimize
drug solubility and stability; for parenteral preparations, it is desirable that the
Table 10.2 Concentration range and antimicrobial activity of preservatives commonly used in
pharmaceutical products
S.
no. Additives
Concentration range
(%)
Antimicrobial activity (minimum inhibitory
concentration (MIC), mg/mL)
Gram-positive
bacteria
Staphylococcus
aureus (S. aureus)
Gram-negative bacteria
Escherichia coli (E. coli)/
Pseudomonas aeruginosa
P.aeruginosa)
1. Benzyl alcohol 0.75–5% 25 2000/2000
2. Chlorobutanol 0.25–0.5% 650
a
1000
a
3. m-Cresol 0.1–0.315% Not specied Not specied
4. Methylparaben 0.05–0.18% 2000 1000/4000
5. Phenol 0.15–0.5% Not specied Not specied
6. 2-Phenoxyethanol 0.50% 8500 3600/3200
7. Propylparaben 0.005–0.1% 500 (100–500)/(>1000)
8. Thimerosal 0.003–0.012% 0.2 4/8
9. Benzalkonium
chloride
0.02% w/v Not specied Not specied
10. Benzethonium
chloride
0.01% Not specied Not specied
11. Myristyl-gamma-
picolinium chloride
0.0195–0.169%
w/v
Not specied Not specied
12. Phenylmercuric
nitrate
0.001% Not specied Not specied
a
MIC values are not specic for S. aureus, E. coli, and P. aeruginosa
S. Shilpi et al.

253
product pH be close to physiologic pH.Injectable products should have a pH value
between 3.0 and 9.0 prior to administration. Buffer systems for parenteral consist of
either a weak base and the salt of a weak base or a weak base or a weak acid and the
salt of weak acid.
Sterile solutions administered intravenously in 100mL or more quantities are
known as large volume parenterals or LVPs. Typically, these solutions provide
nutrients, drugs, electrolytes, and uids to the circulation while ensuring complete
rapid absorption (Hoyois etal. 2021). In many benecial scenarios, LVPs are cru-
cial, especially for patients who cannot swallow tablets or other nutrition (Hu
etal. 2020).
LVPs are vital in clinical practice for rehydration therapy, maintaining uid bal-
ance during surgeries, and supporting patients in intensive care who cannot eat or
drink. They are also crucial in managing chronic conditions like kidney disease
(Preiser etal. 2021). A key aspect of LVPs is the inclusion of additives such as vita-
mins, electrolytes (sodium, potassium, calcium, magnesium), trace elements, amino
acids, and medications. These additives address deciencies, enhance recovery, and
support overall health by maintaining cellular function, muscle contraction, and
nerve transmission.
Vitamins such as B complex, vitamin C, and vitamin D are added to LVPs to
support metabolism, collagen synthesis, immune function, and calcium absorption
(Anon n.d.-b). These are crucial for patients with severe deciencies or those on
long-term parenteral nutrition (Pecora etal. 2020). Trace elements like zinc, copper,
manganese, and selenium support enzymatic functions, antioxidant defenses,
wound healing, and immune health (Berger etal. 2021). Amino acids and proteins
Table 10.3 Antioxidants in parenterals
S. no.
Antioxidant
Concentration range %
Reducing agents
1. Ascorbic acid 0.02–0.1
2. Sodium bisulte 0.1–0.15
3. Sodium metabisulte 0.1–0.15
4. Sodium formaldehyde sulfoxide 0.1–0.15
5. Thiourea 0.005
Blocking agents
1. Ascorbic acid esters 0.01–0.015
2. Butylated hydroxytoluene (BHT) 0.005–0.02
3. Tocopherols 0.05–0.075
Synergist agents
1. Ascorbic acid 0.01–0.05
2. Citric acid 0.005–0.01
3. Citraconic acid 0.03–0.45
4. Phosphoric acid 0.005–0.01
5.. Tartaric acid 0.01–0.02
Chelating agent
1. Ethylenediaminetetraacetic acid salts 0.01–0.075
10 Sterile Products andAdmixtures

254
in parenteral nutrition solutions aid tissue repair and growth, especially in critically
ill patients. Medications can be added to LVPs for rapid and precise drug delivery,
essential for pain management, chemotherapy, and antibiotic therapy (Eggersdorfer
etal. 2022).
10.2.4 Vitamins
Vitamins are vital for several physiological activities. They are included in large
volume parenterals (LVPs) to make sure patients receive the nutrients they require,
particularly in cases when oral consumption is not practical (Tubic-Grozdanis and
Krämer 2015). For severely sick patients or those undergoing long-term therapy,
adding vitamins to LVPs can help avoid decits and maintain general health.
Intravenous nutrition replacement therapy is a crucial intervention for patients
whose diet is inadequate in providing essential nutrients since it aids in both main-
taining health and rehabilitation (Tubic-Grozdanis and Krämer 2023).
10.2.4.1 Vitamin B Complex
Water-soluble vitamins, which are crucial to cell metabolism and energy generation,
make up the vitamin B complex. B1 (thiamine), B2 (riboavin), B3 (niacin), B5
(pantothenic acid), B6 (pyridoxine), B7 (biotin), B9 (folic acid), and B12 (cobala-
min) are the elements that make up this complex (Serventi etal. 2023). Every vita-
min in the complex performs a different role, from helping the human body convert
food into energy to encouraging the production of red blood cells and cognitive
function. Vitamin B complex supplementation is especially essential to patients
receiving LVPs who possess greater metabolic needs, such as those recuperating
from surgery or long-term medical conditions (Wijaya etal. 2015). For example,
folic acid and thiamine are essential in avoiding decits that may cause serious
neurological disorders (Calder et al. 2022). Patients who are unable to consume
enough nutrients orally can have their nutritional needs met by receiving a sufcient
amount of these vitamins through LVPs, which promotes their overall health and
faster recovery.
10.2.4.2 Vitamin C
Ascorbic acid, commonly referred to as vitamin C, is a strong antioxidant which
promotes collagen formation, boosts the immune system, and improves the absorp-
tion of iron from food (Johnson and Probert 2014). It is essential for the healing of
wounds and the defense of cells against oxidative damage. Vitamin C is routinely
included in large volume parenterals (LVPs) to assist patients who are under inten-
sive medical treatment or suffering from severe infections or elevated oxidative
stress (Carr etal. 2017; Lee etal. 2023). Vitamin C’s antioxidant properties aid in
the neutralization of free radicals, minimizing cellular damage and improving
recovery. This makes it especially advantageous for preserving general health while
assisting the recuperation of patients who are in critical condition by ensuring they
receive adequate nutritional support throughout therapies (Assouline etal. 2021).
S. Shilpi et al.

255
10.2.4.3 Vitamin D
Bone condition and proper equilibrium of calcium depend on vitamin D.This helps
the gastrointestinal system absorb calcium and phosphorus, which are crucial for
preserving bone density and preventing diseases like osteoporosis (Anon n.d.-c).
This disorders result in deciencies of calcium. Vitamin D supplementation is espe-
cially crucial for patients receiving LVP who are immobile or have limited exposure
to sunlight. Keeping these individuals’ vitamin D levels adequate helps with the
healthy development of their bones and overall musculoskeletal health. For patients
who are unable to obtain enough vitamin D from natural sources, this is essential for
promoting their recovery and overall health and minimizing issues linked to
extended immobility (Anon n.d.-a).
In addition to vitamins, large volume parenteral (LVPs) may contain various
other additives to meet specic medical needs. These include electrolytes like
sodium, potassium, and magnesium, which are crucial for uid balance, nerve func-
tion, and muscle contraction. Amino acids are added for protein synthesis, tissue
repair, and immune function. Trace elements such as zinc, copper, and selenium are
vital for enzymatic reactions and immune defense. Minerals like calcium and phos-
phorus are essential for bone health and metabolic processes. These additives ensure
comprehensive nutritional support for patients, particularly those unable to intake
nutrients orally.
10.2.5 Electrolytes
Electrolytes are electrically charged minerals found throughout body uids that are
essential to several biological processes. They support the body’s hydration needs,
blood pressure and acidity regulation, neuron and muscle function, and tissue repair.
Electrolytes are added to large volume parenterals (LVPs) to help patients maintain
the right electrolyte balance, especially when oral intake is not feasible. The impor-
tant electrolytes that are added to LVPs are described below:
10.2.6 Sodium
Sodium is an important extracellular electrolyte that is necessary for neuron activ-
ity, blood pressure control, and uid balance. It regulates the amount of water in and
around cells, which is essential for healthy neuron and muscle function. Large vol-
ume parenterals (LVPs) frequently contain salt in order to avoid hyponatremia, or
low sodium levels, in patients who are unable to swallow food or uids. For those
who suffer from renal disease, dehydration, or other illnesses that cause consider-
able uid loss, this is especially important. Sodium chloride is frequently utilized in
LVPs to promote overall cellular function and patient health by ensuring appropri-
ate hydration and maintaining normal blood pressure levels.
10 Sterile Products andAdmixtures

256
10.2.7 Potassium
Potassium is an intracellular electrolyte which is crucial to healthy cell division,
nerve impulse transmission, and heart contraction. It regulates the osmotic pressure
and acid-base equilibrium in cells. Large volume parenterals (LVPs) usually contain
potassium to avoid hypokalemia (low potassium levels), which can be caused by
prolonged vomiting, diuretics, or diarrhea. Sustaining sufcient potassium levels is
essential for healthy heart function, as low levels can cause arrhythmias and other
heart problems. To maintain healthy patient outcomes and ensure efcient cellular
function, potassium chloride is frequently utilized in LVPs.
10.2.8 Calcium
For healthy bones, blood clotting, muscular contraction, and nerve interactions, cal-
cium is essential. It primarily accumulates as structural support in teeth and bones.
Calcium is added to LVPs in order to avoid hypocalcemia, or low calcium levels,
which can be caused by a number of illnesses, including pancreatitis, renal failure,
and parathyroid difculties. Enough calcium is necessary to maintain the neurologi-
cal, muscular, and cardiovascular systems in optimal working order. Common types
of calcium utilized in LVPs to help patients maintain appropriate calcium levels and
support general physiological functions include calcium gluconate and calcium
chloride.
10.2.9 Magnesium
Magnesium is a crucial electrolyte that the body uses for more than 300 metabolic
processes, such as blood glucose management, muscle and neuron function, protein
synthesis, and blood pressure regulation. It also contributes to the synthesis of
energy and the development of bone integrity. Magnesium is necessary to add in
LVPs to avoid hypomagnesemia. The magnesium deciency is occured by long-
term diuretic consumption, malnutrition, or chronic alcoholism. A specic kind of
magnesium that is frequently utilized in LVPs is magnesium sulfate, which supports
general metabolic processes and helps to guarantee adequate muscle and nerve
function.
10.2.10 Chloride
A vital extracellular electrolyte, chloride interacts closely with sodium to maintain
the body’s uid balance, osmotic pressure, and acid-base equilibrium. It is a crucial
part of the hydrochloric acid in gastric juice, which is required for digestion.
Chloride is included in LVPs to avoid hypochloremia, or low chloride levels, which
can be brought on by prolonged vomiting, diarrhea, or dehydration. Chloride, which
S. Shilpi et al.

257
is often found as sodium chloride, supports general homeostasis and biological
function by assisting in the maintenance of appropriate blood pressure, pH balance,
and hydration.
10.2.11 Copper, Iron, andZinc
A vital trace element involved in numerous biological processes is zinc. It is essen-
tial for wound healing, immunological response, protein synthesis, DNA synthesis,
and cell division. Moreover, zinc is necessary to preserve good taste and fragrance.
It helps antioxidant defense systems and metabolic activities as a cofactor for more
than 300 enzymes. Zinc supplementation is essential for patients receiving LVP
who have deciencies, which can be brought on by poor nutrition, malabsorption
syndromes, or higher-than-normal physiological demands from conditions includ-
ing trauma, surgery, or long-term illnesses. Zinc deciency can cause growth retar-
dation, delayed wound healing, and reduced immunological response; consequently
including zinc in LVPs is crucial for the general health and recovery of patients.
Essential mineral copper can be found as a dietary supplement or naturally
occurring in some foods. It functions as a cofactor for a number of cuproenzymes,
which are enzymes involved in the creation of connective tissue, energy production,
iron metabolism, neuropeptide activation, and neurotransmitter synthesis (Collins
2014). The mineral iron can be found as a nutritional supplement, added to some
food products, or found naturally in a variety of foods. Hemoglobin, a protein found
in erythrocytes (red blood cells) that carries oxygen from the lungs to the tissues,
requires iron as a necessary component (Aggett 2012). Zinc is an all-around body
vitamin that supports healthy metabolism and the immune system. Your sense of
smell and taste, as well as the healing of wounds, depends on zinc. Your body nor-
mally obtains enough zinc from a diverse diet. Zinc-rich foods include poultry, red
meat, and breakfast cereals with added nutrients. Numerous facets of cellular
metabolism involve zinc. It is necessary for hundreds of enzymes to catalyze their
activities and is involved in wound healing, immune system function, protein and
DNA synthesis, and cell signaling and division. In addition to being involved in
taste perception, zinc also promotes healthy growth and development during preg-
nancy, infancy, childhood, and adolescence (MacDonald 2000).
The following range of nal concentrations of copper, iron, and zinc was added
to a parenteral admixture consisting of 20% intralipid (intravenous fat emulsion); it
is a non-pyrogenic, highly sterile preparation for i.v. injection to deliver the required
calories and fatty acids. Also, it consists of 25% Azonutril 25 (utilized to treat bacte-
rial infections of the skin, soft dermis, respiration airways, tonsils, alveoli, ears, and
throat). Additionally, enteric fever that arises due to intestinal infections, pneumonia
(a viral fever), and tracheal infections brought on by coming into contact with an
infected individual is treated with it. The admixture also contains 37.5% glucose-
6-PO
4
. The rest of the compositions were copper (0.24mg/L), iron (0.50mg/L), and
zinc (2.00mg/L) (Harraki etal. 1993; Desai etal. 2007; Blicharska etal. 2016). The
combination, including the trace elements in the gluconate form, showed good
10 Sterile Products andAdmixtures

258
stability, according to the pH determination. After a week of storage at both tem-
peratures, a notable reduction in the pH of the combination containing the trace
elements as chlorides was observed. The ndings obtained regarding physicochemi-
cal stability were validated by occulation kinetics. Furthermore, the kinetics
showed that there is very little chance of coalescence processes in every scenario.
According to B.Harraki etal. (1993), ndings suggested that at a temperature of 4
and 25°C, the two types of combinations are stable for 7days. For extended stor-
age, nevertheless, combinations that include trace elements in gluconate form ought
to be selected. For many enzymatic processes, including those affecting iron metab-
olism, the development of connective tissue, the synthesis of neurotransmitters, and
energy generation, copper is an essential trace metal. It is essential for preserving
the neurological and cardiovascular systems’ health. Superoxide dismutase, a cru-
cial antioxidant enzyme that protects cells from injury from free radicals, contains
copper. Copper deciency may be occured due to malabsorption, and certain medi-
cal problems, which may be avoided by adding copper as supplements in LVPs.
Anemia, neutropenia, anomalies in the bones, and brain diseases can all result from
a copper shortage. Hence, sufcient copper supplementation in LVPs guarantees
appropriate enzymatic activity and preservation of general health.
10.2.12 Manganese
Manganese is a trace element that helps create bones, coagulate blood, and lessen
inammation. It functions as a cofactor for a number of enzymes, including those
that are involved in the metabolism of cholesterol, amino acids, and carbohydrates.
By triggering superoxide dismutase, manganese also aids in antioxidant defense.
Manganese is also necessary to add in LVPs to help individuals who have higher
physiological needs or nutritional decits. Decreased growth, skeletal abnormali-
ties, changes in the metabolism of fats and carbohydrates, and oxidative stress can
all be outcomes of a manganese deciency. Manganese is a component of LVPs that
supports appropriate enzymatic activity, bone health, and metabolic processes, all of
which contribute to the overall recovery and well-being of patients.
10.2.13 Selenium
The correct operation of antioxidant enzymes, such as glutathione peroxidases,
which protect cells from oxidative damage, depends on selenium, a vital trace ele-
ment. It is also essential for immunological response, DNA synthesis, and thyroid
hormone metabolism. Selenium is administered to LVPs to avoid deciencies that
might develop in individuals receiving parenteral nutrition for an extended period of
time or who have issues with malabsorption. Thyroid dysfunction weakened
immune system, and Keshan disease—a kind of cardiomyopathy—can result from
a selenium decit. Sufcient selenium supplementation in LVPs promotes immune
S. Shilpi et al.

259
system health, thyroid function, and antioxidant defense, all of which are benecial
to the general well-being and recuperation of patients.
10.2.14 Amino Acids
Amino acids, fundamental for protein synthesis, are vital for tissue repair, immune
function, enzyme and hormone production, and various metabolic processes. They
are categorized into essential (must be obtained from diet) and nonessential (synthe-
sized by the body). In large volume parenterals (LVPs), amino acids are included to
provide necessary protein substrates, particularly for patients unable to take suf-
cient protein orally due to severe illness, surgery, or gastrointestinal issues. This
ensures patients receive essential nutrients to support vital bodily functions and
promote recovery.
Large volume parenterals (LVPs) containing amino acids have several advan-
tages. First of all, in bedridden or immobile patients in danger of muscle loss, LVPs
assist in muscular development and maintenance. Maintaining muscle mass is
essential for recuperation and rehabilitation, especially for patients who are severely
ill or have recently undergone surgery. Second, amino acids are important for the
healing of injuries. They supply the elements required for both the synthesis of new
tissue and the restoration of damaged tissue. This is crucial for those recuperating
after surgery or trauma since it expedites the healing process and lowers the possi-
bility of problems. Amino acids are also essential for immunological function. They
aid in the body’s ability to generate white blood cells, antibodies, and other immune-
supporting molecules that ght infections. This is especially important for individu-
als whose immune systems are weakened or who are receiving therapies like
chemotherapy, which can reduce immunity.
10.2.15 Carbohydrates
The body uses carbohydrates as its main energy source, which are essential for
maintaining both general health and metabolic processes. Carbohydrates are added
to large volume parenterals (LVPs) to make sure patients get enough energy when
oral intake is limited. They are vital in preserving steady blood glucose levels,
which are necessary for normal brain function and the synthesis of all cellular
energy. LVPs assist in stopping the deterioration of muscle tissue by intravenously
supplying carbs, preserving proteins for their essential roles in immune response
and tissue regeneration.
10.2.16 Dextrose
Glucose, or dextrose, is a basic sugar that’s frequently added to LVPs to provide
them an instant energy boost. It enters the bloodstream fast, which aids in raising
10 Sterile Products andAdmixtures
Соседние файлы в папке Библиотека им академика М.И. Перельмана
